Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells.
Muñoz L, Nomdedéu JF, Villamor N, Guardia R, Colomer D, Ribera JM, Torres JP, Berlanga JJ, Fernández C, Llorente A, Queipo de Llano MP, Sánchez JM, Brunet S, Sierra J; Spanish CETLAM Group. Muñoz L, et al. Among authors: berlanga jj. Leukemia. 2003 Jan;17(1):76-82. doi: 10.1038/sj.leu.2402708. Leukemia. 2003. PMID: 12529663
Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients.
Perea G, Domingo A, Villamor N, Palacios C, Juncà J, Torres P, Llorente A, Fernández C, Tormo M, Queipo de Llano MP, Bargay J, Gallart M, Florensa L, Vivancos P, Martí JM, Font L, Berlanga J, Esteve J, Bueno J, Ribera JM, Brunet S, Sierra J, Nomdedéu JF; CETLAM GroupSpain. Perea G, et al. Leuk Res. 2005 Oct;29(10):1109-16. doi: 10.1016/j.leukres.2005.02.015. Leuk Res. 2005. PMID: 16095690
Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
Perea G, Lasa A, Aventín A, Domingo A, Villamor N, Queipo de Llano MP, Llorente A, Juncà J, Palacios C, Fernández C, Gallart M, Font L, Tormo M, Florensa L, Bargay J, Martí JM, Vivancos P, Torres P, Berlanga JJ, Badell I, Brunet S, Sierra J, Nomdedéu JF; Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel. Perea G, et al. Among authors: berlanga jj. Leukemia. 2006 Jan;20(1):87-94. doi: 10.1038/sj.leu.2404015. Leukemia. 2006. PMID: 16281071
CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.
Pérez-García A, Brunet S, Berlanga JJ, Tormo M, Nomdedeu J, Guardia R, Ribera JM, Heras I, Llorente A, Hoyos M, Esteve J, Besalduch J, Bueno J, Sierra J, Gallardo D; Grupo cooperativo para el estudio y tratamiento de las leucemias agudas. Pérez-García A, et al. Among authors: berlanga jj. Leukemia. 2009 Mar;23(3):486-91. doi: 10.1038/leu.2008.339. Epub 2008 Dec 18. Leukemia. 2009. PMID: 19092854 Clinical Trial.
Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.
Brunet S, Esteve J, Berlanga J, Ribera JM, Bueno J, Martí JM, Bargay J, Guardia R, Juliá A, Granena A, Montserrat E, Sierra J; Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias. Brunet S, et al. Haematologica. 2004 Aug;89(8):940-9. Haematologica. 2004. PMID: 15339677 Clinical Trial.
Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation.
Gallardo D, De la Cámara R, Torres A, Brunet S, Jiménez A, Vallejo JC, Sanz G, Serrano D, Carreras E, Martín C, Sanz-Rodríguez C, Sierra J, Espigado I, Caballero D, Berlanga JJ. Gallardo D, et al. Among authors: berlanga jj. Leukemia. 2004 Jun;18(6):1165-7. doi: 10.1038/sj.leu.2403397. Leukemia. 2004. PMID: 15156157 No abstract available.
Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation.
Gallardo D, De la Cámara R, Torres A, Brunet S, Jiménez A, Vallejo JC, Sanz G, Serrano D, Carreras E, Martín C, Sanz-Rodríguez C, Sierra J, Espigado I, Caballero D, Berlanga JJ. Gallardo D, et al. Among authors: berlanga jj. Leukemia. 2004 May;18(5):1031-4. doi: 10.1038/sj.leu.2403344. Leukemia. 2004. Corrected and republished in: Leukemia. 2004 Jun;18(6):1165-7. doi: 10.1038/sj.leu.2403397 PMID: 15029209 Corrected and republished. No abstract available.
Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
Gallardo D, García-López J, Sureda A, Canals C, Ferra C, Cancelas JA, Berlanga JJ, Brunet S, Boqué C, Picón M, Torrico C, Amill B, Martino R, Martínez C, Martín-Henao G, Domingo-Albós A, Grañena A. Gallardo D, et al. Among authors: berlanga jj. Bone Marrow Transplant. 1997 Dec;20(11):945-52. doi: 10.1038/sj.bmt.1701008. Bone Marrow Transplant. 1997. PMID: 9422473
Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications.
Ferrà C, de Sanjosé S, Lastra CF, Martí F, Mariño EL, Sureda A, Brunet S, Gallardo D, Berlanga JJ, García J, Grañena A. Ferrà C, et al. Among authors: berlanga jj. Bone Marrow Transplant. 1997 Dec;20(12):1075-80. doi: 10.1038/sj.bmt.1701023. Bone Marrow Transplant. 1997. PMID: 9466281 Clinical Trial.
52 results